Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Papua New Guinea facing COVID-19 crisis as infection rate rises

Published 15/03/2021, 04:06 pm

By Kirsty Needham

SYDNEY, March 15 (Reuters) - Half of COVID-19 tests from the Pacific island nation of Papua New Guinea (PNG) processed by Australia have been positive, the leader of Queensland state said on Monday, prompting calls for faster vaccine delivery.

PNG's Western Province lies within a few kilometres (miles) of Australia's northern border, and Queensland laboratories are assisting to investigate the worsening outbreak.

Queensland state Premier Annastacia Palaszczuk said Papua New Guinea was "on the doorstep" and she held real concern about the rising infection rate there.

"Out of the 500 tests that our health authorities have done for PNG, 250 have come back positive," Palaszczuk told reporters on Monday.

Ninety new cases were recorded in Papua New Guinea on Saturday by its government, and a World Health Organisation weekly update was due to be released later on Monday.

PNG Prime Minister James Marape is also expected to make a statement on the worsening epidemic.

The island nation has recorded a total of 2,173 cases and 21 deaths since the pandemic began, according to a PNG government statement. COVID infections have been recorded in 17 provinces.

The latest outbreak is centred on the National Capital District in Port Moresby, and comes after the nation mourned the death of its first prime minister, Sir Michael Somare.

Papua New Guinea granted regulatory approval for the AstraZeneca (NASDAQ:AZN) COVID-19 vaccine last week. The vaccine is not planned to be rolled out until late April, through the COVAX initiative which has allocated one million doses to the Pacific.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Brendan Crabb, chairman of the Pacific Friends of Global Health, said Papua New Guinea is experiencing exponential growth in COVID-19 cases and an emergency plan was needed to assist its small and overstretched health system.

"We were already at this absolute crisis point for the country. Added to that is the Grand Chief Michael Somare's commemorations over the past week, which if ever there was a super-spreading event in the middle of an already big epidemic, clearly that's it," he told Reuters in a telephone interview.

Crabb, the chief executive of the Burnet Institute which works on infectious disease programmes in Papua New Guinea, said Australia had made good commitments to purchasing vaccines for Papua New Guinea, but these needed to be delivered faster.

"We need Papua New Guinea's 5,000 or so health care workers vaccinated in the next week or two," he said.

He said if health services are overwhelmed by COVID-19 the treatment of malaria, HIV, and tuberculosis would also collapse.

Australia on Friday committed to spending $77 million to distribute vaccines in the Indo Pacific under an initiative by the Quad group, which also includes the United States, Japan and India. This is additional to the $407 million Canberra has pledged for regional vaccine access to nine Pacific Island countries and Timor-Leste.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.